[The efficacy of using prolonged-action L-asparaginase in a treatment program for acute lymphoblastic leukemia in adults].
Tretiak
N M
NM
Kupchenko
T N
TN
Politov
I Z
IZ
Zubryts'ka
T B
TB
D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001215:Asparaginase / Q000009:adverse effects / Q000627:therapeutic use*; D003692:Delayed-Action Preparations; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010592:Pharmaceutic Aids; D011092:Polyethylene Glycols; D012008:Recurrence; D012074:Remission Induction; D013997:Time Factors
D000970:Antineoplastic Agents; D003692:Delayed-Action Preparations; D010592:Pharmaceutic Aids; D011092:Polyethylene Glycols; D001215:Asparaginase